Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment

Neurochemical Research

Volumn 36, Issue 5, 2011, Pages 922-923

  Ghanizadeh, Ahmad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

GABA; Glutamate; Glycine; Pervasive developmental disorder; Receptor

Indexed keywords

4 AMINOBUTYRIC ACID; GHRELIN; GLUTAMIC ACID; GLYCINE; LEPTIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AUTISM; CALCIUM TRANSPORT; CHANNEL GATING; DRUG TARGETING; EXCITOTOXICITY; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; NEUROTRANSMISSION; NONHUMAN; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

AUTISTIC DISORDER; GLYCINE; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79954433555     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0381-2     Document Type: Review

References (25)

1. Nagy K et al (2010) Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter Type-1 inhibitor Org-24461 and Risperidone. Neurochem Res
2. TV Waseem SV Fedorovich 2010 Presynaptic glycine receptors influence plasma membrane potential and glutamate release Neurochem Res 35 8 1188 1195 20431942 10.1007/s11064-010-0174-7 1:CAS:528:DC%2BC3cXlsVWjsro%3D
3. K Socala, et al. 2010 Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models Pharmacol Rep 62 2 392 397 20508295 1:CAS:528:DC%2BC3cXhtVGks7%2FO
4. A Shinohe, et al. 2006 Increased serum levels of glutamate in adult patients with autism Prog Neuropsychopharmacol Biol Psychiatry 30 8 1472 1477 16863675 10.1016/j.pnpbp.2006.06.013 1:CAS:528:DC%2BD28XhtFCjsLnE (Pubitemid 44634960)
5. CJ McDougle, et al. 2005 Neurochemistry in the pathophysiology of autism J Clin Psychiatr 66 Suppl 10 9 18 1:CAS:528:DC%2BD28XosVOhsw%3D%3D (Pubitemid 43133209)
6. S Aldred, et al. 2003 Plasma amino acid levels in children with autism and their families J Autism Dev Disord 33 1 93 97 12708584 10.1023/A: 1022238706604 (Pubitemid 36323144)
7. CJ McBain, et al. 1989 Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes Mol Pharmacol 36 4 556 565 2554111 1:CAS:528:DyaK3cXkvVyrug%3D%3D (Pubitemid 19273831)
8. NW Kleckner R Dingledine 1988 Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes Science 241 4867 835 837 2841759 10.1126/science.2841759 1:CAS:528:DyaL1cXlt1aqurc%3D
9. PL Wood 2005 The NMDA receptor complex: a long and winding road to therapeutics IDrugs 8 3 229 235 15772895 1:CAS:528:DC%2BD2MXjtFensLs%3D
10. PK Stanton, et al. 2009 Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13 Neuroreport 20 13 1193 1197 19623090 10.1097/WNR.0b013e32832f5130 1:CAS:528:DC%2BD1MXhtVSgur3J
11. R Bergeron, et al. 1998 Modulation of N-methyl-D-aspartate receptor function by glycine transport Proc Natl Acad Sci USA 95 26 15730 15734 9861038 10.1073/pnas.95.26.15730 1:CAS:528:DyaK1MXhvFehug%3D%3D (Pubitemid 29018768)
12. DC Javitt 2006 Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients Curr Opin Psychiatry 19 2 151 157 16612195 10.1097/01.yco.0000214340.14131.bd (Pubitemid 44406126)
13. E Pastural, et al. 2009 Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism Prostaglandins Leukot Essent Fatty Acids 81 4 253 264 19608392 10.1016/j.plefa.2009.06.003 1:CAS:528:DC%2BD1MXht1ais7fM
14. Harada M et al (2010) Non-Invasive evaluation of the gabaergic/ glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord. doi: 10.1007/s10803-010-1065-0
15. KS Lam MG Aman LE Arnold 2006 Neurochemical correlates of autistic disorder: a review of the literature Res Dev Disabil 27 3 254 289 16002261 10.1016/j.ridd.2005.03.003
16. I Maezawa LW Jin 2010 Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate J Neurosci 30 15 5346 5356 20392956 10.1523/JNEUROSCI.5966-09.2010 1:CAS:528:DC%2BC3cXlvVagtL4%3D
17. RL Blaylock A Strunecka 2009 Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders Curr Med Chem 16 2 157 170 19149568 10.2174/092986709787002745 1:CAS:528:DC%2BD1MXjsFGqsro%3D
18. H Niederhofer 2007 Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism J Clin Psychopharmacol 27 3 317 318 17502791 10.1097/01.jcp.0000270082.30500.69 (Pubitemid 46763326)
19. CA Erickson JE Chambers 2006 Memantine for disruptive behavior in autistic disorder J Clin Psychiatr 67 6 1000 10.4088/JCP.v67n0619h (Pubitemid 44049107)
20. MG Chez, et al. 2007 Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability J Child Neurol 22 5 574 579 17690064 10.1177/0883073807302611 (Pubitemid 46951501)
21. C Ikonomidou L Turski 2002 Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1 6 383 386 12849400 10.1016/S1474-4422(02)00164-3 1:CAS:528:DC%2BD3sXkvFKrtr8%3D (Pubitemid 37159164)
22. A Ghanizadeh 2010 Transplantation of GABAergic cell line as a novel hypothesized treatment for autism Epilepsy Behav 19 664 20934920 10.1016/j.yebeh.2010.09.009
23. Ghanizadeh A, c-kit+ cells transplantation as a new treatment for autism, a novel hypothesis with important research and clinical implication. J Autism Dev Disord, accepted for publication
24. A Ghanizadeh 2011 Leptin as a new approach for treatment for autism and epilepsy, a hypothesis with clinical implications Brain Dev 33 92 20822869 10.1016/j.braindev.2010.08.003
25. Ghanizadeh A, Ghrelin as a promising therapeutic target for co-occurring autism and epilepsy. doi: 10.1016/j.yebeh.2010.12.009